Literature DB >> 8570999

Medicine and mechanisms in altitude sickness. Recommendations.

J H Coote1.   

Abstract

Acute mountain sickness (AMS) has long been recognised as a potentially life-threatening condition afflicting otherwise healthy normal individuals who ascend rapidly to high altitude where the partial pressure of oxygen (pO2) in the air is reduce. The symptoms of AMS (e.g. headache, poor appetite and nausea, fatigue and weakness, dizziness or light-headedness and poor sleep) are probably a consequence of disturbances in fluid balance brought about by severe tissue hypoxia. AMS can be prevented by an adequately slow ascent, which is the best method, but for those with limited time there are several drug therapies that provide a relatively good protection. Acetazolamide (250 mg twice daily or 500 mg slow release once daily), taken before and during, ascent is probably the treatment of choice; it improves gas exchange and exercise performance and reduces the symptoms of AMS in most individuals. Dexamethasone (4 mg, 4 times daily) is more of value for short term treatment or prevention, and should never be used for more than 2 to 3 days. Prophylactic use of progesterone looks promising, but more studies are required.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8570999     DOI: 10.2165/00007256-199520030-00003

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  41 in total

1.  RESPIRATORY CONTROL AT HIGH ALTITUDE SUGGESTING ACTIVE TRANSPORT REGULATION OF CSF PH.

Authors:  J W SEVERINGHAUS; R A MITCHELL; B W RICHARDSON; M M SINGER
Journal:  J Appl Physiol       Date:  1963-11       Impact factor: 3.531

2.  Enhanced exercise-induced rise of aldosterone and vasopressin preceding mountain sickness.

Authors:  P Bärtsch; M Maggiorini; W Schobersberger; S Shaw; W Rascher; J Girard; P Weidmann; O Oelz
Journal:  J Appl Physiol (1985)       Date:  1991-07

3.  Effect of carbon dioxide in acute mountain sickness: a rediscovery.

Authors:  T C Harvey; M E Raichle; M H Winterborn; J Jensen; N A Lassen; N V Richardson; A R Bradwell
Journal:  Lancet       Date:  1988-09-17       Impact factor: 79.321

4.  Increased capillary fragility at high altitude.

Authors:  D J Hunter; J R Smart; L Whitton
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-11

5.  Acute mountain sickness.

Authors:  A D Wright; R F Fletcher
Journal:  Postgrad Med J       Date:  1987-03       Impact factor: 2.401

Review 6.  Corticosteroid therapy in patients with cerebral tumors: benefits, mechanisms, problems, practicalities.

Authors:  P H Gutin
Journal:  Semin Oncol       Date:  1975-03       Impact factor: 4.929

7.  Severe acute mountain sickness.

Authors:  J G Dickinson
Journal:  Postgrad Med J       Date:  1979-07       Impact factor: 2.401

8.  Mountain sickness, retinal haemorrhages, and acclimatisation on Mount Everest in 1975.

Authors:  C Clarke; J Duff
Journal:  Br Med J       Date:  1976-08-28

9.  Spironolactone and acute mountain sickness.

Authors:  T T Currie; P H Carter; W L Champion; G Fong; J K Francis; I H McDonald; R K Newing; I N Nunn; R N Sisson; M Sussex; R F Zacharin
Journal:  Med J Aust       Date:  1976-07-31       Impact factor: 7.738

10.  Acetazolamide in control of acute mountain sickness.

Authors: 
Journal:  Lancet       Date:  1981-01-24       Impact factor: 79.321

View more
  2 in total

1.  Medical provision and usage for the 1999 Everest marathon.

Authors:  D G Buckler; F O'Higgins
Journal:  Br J Sports Med       Date:  2000-06       Impact factor: 13.800

2.  Auto-PEEP in the therapy of AMS in one person at 4,330 m.

Authors:  Markus Tannheimer; Sibylle Tannheimer; Alfred Thomas; Michael Engelhardt; Roland Schmidt
Journal:  Sleep Breath       Date:  2008-12-04       Impact factor: 2.816

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.